DeepMed Research

Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults

Phase 1

Conditions: Type II Diabetes

Interventions: Drug: CKD-387
Drug: D484

First Posted Date: 2018-08-24

Last Posted Date: 2018-08-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 36

Registration Number: NCT03646799

Locations: 🇰🇷
Yonsei University Severance Hospital, Soeul, Korea, Republic of

The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes

Phase 3

Conditions: Type2 Diabetes

Interventions: Drug: Placebo
Drug: CKD-501 0.5mg

First Posted Date: 2018-08-22

Last Posted Date: 2018-08-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 240

Registration Number: NCT03641352

Locations: 🇰🇷
The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes

Phase 3

Conditions: Type2 Diabetes

Interventions: Drug: CKD-501 0.5mg
Drug: Placebo

First Posted Date: 2018-08-13

Last Posted Date: 2018-08-13

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 240

Registration Number: NCT03627182

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308

Phase 1

Completed

Conditions: Diabetes Mellitus, Type II

Interventions: Drug: D308, CKD-501

First Posted Date: 2018-08-06

Last Posted Date: 2018-11-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 41

Registration Number: NCT03616392

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects

Phase 1

Completed

Conditions: Hypertension
Dyslipidemias

Interventions: Drug: D013, D326 and D337
Drug: D013
Drug: D326 and D337

First Posted Date: 2018-08-01

Last Posted Date: 2018-10-05

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 69

Registration Number: NCT03609606

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mg

Phase 1

Conditions: Type II Diabetes Mellitus

Interventions: Drug: D308 10mg Tab.
Drug: CKD-380 10mg Tab.

First Posted Date: 2018-07-26

Last Posted Date: 2018-07-26

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 34

Registration Number: NCT03601910

Locations: 🇰🇷
The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet

Phase 3

Completed

Conditions: Hypertensive Patients With Dyslipidemia

Interventions: Drug: CKD-330
Drug: Placebo of CKD-330
Drug: Placebo of D086
Drug: D086
Drug: Placebo of D723
Drug: D723

First Posted Date: 2018-07-12

Last Posted Date: 2019-07-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 154

Registration Number: NCT03583905

Locations: 🇰🇷
Gachon University Gil Hospital, Incheon, Korea, Republic of
🇰🇷
Catholic University Seoul St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 13 locations

CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)

Phase 1

Completed

Conditions: Central Nervous System Diseases

Interventions: Drug: Memantine Tab. 10mg
Drug: Memantine Tab. 10mg + Donepezil Tab. 10mg

First Posted Date: 2018-06-26

Last Posted Date: 2018-06-26

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 20

Registration Number: NCT03569579

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

A Study to Compare PK, PD and Safety of CKD-381 and D026 in Healthy Subjects

Phase 1

Completed

Conditions: GERD

Interventions: Drug: D026
Drug: CKD-381

First Posted Date: 2018-06-15

Last Posted Date: 2018-10-12

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 41

Registration Number: NCT03558425

Locations: 🇰🇷
Seoul Nat'l University Hospital, Seoul, Korea, Republic of

A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects

Phase 1

Completed

Conditions: GERD

Interventions: Drug: CKD-381(formulation I)
Drug: CKD-381(formulation II)
Drug: D026(Nexium 40mg)

First Posted Date: 2018-02-23

Last Posted Date: 2018-05-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 18

Registration Number: NCT03444402

Locations: 🇰🇷
Seoul University Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy